home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

58.51 -0.56 (-0.95%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

10 Magnificent Stocks That Can Make You Richer in 2025 ↗

January 03, 2025

A new year brings with it new opportunities to grow your wealth on Wall Street.

Via The Motley Fool

NASDAQ:BMRN stands out as a stock that provides good value for the fundamentals it showcases. ↗

December 27, 2024

In a market where value is scarce, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

NASDAQ:BMRN, a growth stock which is not overvalued. ↗

December 24, 2024

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.

Via Chartmill

The Latest Analyst Ratings For Biomarin Pharmaceutical ↗

December 12, 2024

Via Benzinga

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. ↗

December 02, 2024

Despite its growth, NASDAQ:BMRN remains within the realm of affordability.

Via Chartmill

When you look at NASDAQ:BMRN, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

November 22, 2024

In a market where value is scarce, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical ↗

November 15, 2024

Via Benzinga

Peering Into Biomarin Pharmaceutical's Recent Short Interest ↗

November 06, 2024

Via Benzinga

In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical ↗

October 30, 2024

Via Benzinga

Can BioMarin Stock Live Up to Wall Street’s High Expectations?

November 22, 2024

BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?

Via MarketBeat

NASDAQ:BMRN stands out as a growth opportunity that won't break the bank. ↗

November 11, 2024

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) is showing decent growth, but is still valued reasonably.

Via Chartmill

CAMP4 Analyst Highlights Rare Disease Platform Potential ↗

November 05, 2024

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts project $1 billion in revenue for UCD drug by 2036.

Via Benzinga

Topics Initial Public Offering

BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth ↗

October 30, 2024

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts.

Via Benzinga

A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast ↗

October 28, 2024

Via Benzinga

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

October 24, 2024

From Monopar Therapeutics Inc.

Via GlobeNewswire

Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN. ↗

October 18, 2024

NASDAQ:BMRN is showing good growth, while it is not too expensive.

Via Chartmill

NASDAQ:BMRN appears to be flying under the radar despite its strong fundamentals. ↗

October 16, 2024

Investors should take notice ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN)—it offers a great deal for the fundamentals it presents.

Via Chartmill

How Is The Market Feeling About Biomarin Pharmaceutical? ↗

October 15, 2024

Via Benzinga

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗

October 09, 2024

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...

Via Benzinga

Analyst Expectations For Biomarin Pharmaceutical's Future ↗

October 04, 2024

Via Benzinga

3 Oversold Stocks with Big RSI Rebound Potential

October 03, 2024

Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them.

Via MarketBeat

Topics Economy

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today ↗

September 23, 2024

Via Benzinga

(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest ↗

September 10, 2024

Via Benzinga

Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced. ↗

September 26, 2024

Despite its growth, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) remains within the realm of affordability.

Via Chartmill

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish ↗

September 25, 2024

BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139...

Via Benzinga

Investors should take notice of NASDAQ:BMRN—it offers a great deal for the fundamentals it presents. ↗

September 25, 2024

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), an undervalued stock with good fundamentals.

Via Chartmill

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗

September 22, 2024

10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%

Via Benzinga

GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 17, 2024

Via Benzinga

Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term ↗

September 16, 2024

BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by late 2025 due to its dosing schedule and potential safety benefits.

Via Benzinga

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug ↗

September 16, 2024

The companies could soon face off in the growth treatment market for children with a genetic disorder.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com